熱門資訊> 正文
CLARX Therapeutics报告第二季度业绩，引发持续经营疑虑
2024-08-10 04:39
- AgeX Therapeutics press release (NYSE:SER): Q2 EPS $0.51.
- It believes that its cash and cash equivalents as of June 30, 2024 along with the proceeds expected to be received from Juvenescence would not be sufficient to satisfy the company’s anticipated operating and other funding requirements for the twelve months following the filing of Form 10-Q for the three and six months ended June 30, 2024.
- These factors raise substantial doubt regarding the ability of the company to continue as a going concern.
More on AgeX Therapeutics
- Parkinson's-focused Serina Therapeutics, Enable Injections enter partnership
- Financial information for AgeX Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
